About us


ACIES BIO was established in 2006 by a group of senior scientists who brought together many years of industrial experience in large pharmaceutical as well as specialized biotechnology companies. The company received an initial investment by a leading Slovenian angel investor and has since then maintained a cash-flow positive and profitable business record, organically growing its scope of research activities and services.

In 2007 ACIES BIO acquired research facilities at the newly built Technology park Ljubljana. In 2008 ACIES BIO expanded its laboratories at Technology park Ljubljana, where the company’s R&D then included over 400 m2 of state-of-the-art research facilities. In 2011 ACIES BIO incorporated a specialized and highly experienced synthetic chemistry company to expand its services and expertise. In 2013 ACIES BIO initiated a further expansion of its research facilities at the Technology park Ljubljana with an additional 200 m2 research space for synthetic chemistry and DSP facilities. The adaptation of the new laboratory was finalized in the first quarter of 2014.

ACIES BIO has received several awards for its excellence in R&D and services. In 2008 ACIES BIO received the “Slovenian Start:up of the year” award for its achievements. In 2009, in partnership with top Slovenian research institutions, Acies was named one of the two Slovenian Centers of Excellence in the field of life-sciences (CIPKeBiP) and in 2010 it was the founding member of the only Slovenian Competence Center in the Food and Health sector (KC-BRIN). In 2013 ACIES BIO was awarded the “Excellent SME” status, awarded by Slovenian Chambers of Commerce.

In addition to industrial collaborations and contract services, ACIES BIO maintains strong links and research collaborations with national and international academic partners and research institutions, collaborating in basic and applied research, teaching, student exchange programs and promoting industry-academia transfer of innovation, technology and best practice.

Within H2020 SME Innovation Associate project we invite a “Disease Model Development Manager” to join our team.

More >>
European Medicines Agency (EMA) granted orphan medicinal product designation to its lead compound CAB1803 for Pantothenate-kinase-associated neurodegeneration (PKAN)

More >>
Scientists at ACIES BIO made a breakthrough innovation: high-value technology that uses unique and economic bioprocess to convert acid waste whey from dairy factories into high value animal feed products (vitamin B12) and clean water in the same process. Check out Whey2Value!

More >>
Acies Bio received the “Jesenko Award” from Biotechnical Faculty of University of Ljubljana. The award recognizes institutions for their outstanding research work in the field of biotechnology.

ABCloneTM is fast and efficient solution for cloning of large natural and synthetic DNA fragments. We provide ABCloneTM as a stand alone service for getting quickly your long DNA fragment sub-cloned into plasmid vector of your choice.

More >>